Louisiana State Employees Retirement System Invests $3.12 Million in Medpace Holdings, Inc. $MEDP

Louisiana State Employees Retirement System acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 6,500 shares of the company’s stock, valued at approximately $3,121,000.

Other institutional investors have also modified their holdings of the company. AQR Capital Management LLC lifted its holdings in Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after acquiring an additional 324,293 shares during the last quarter. Wasatch Advisors LP grew its stake in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after purchasing an additional 85,517 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Medpace by 19.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after purchasing an additional 60,883 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on MEDP shares. BMO Capital Markets reduced their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Weiss Ratings cut Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Royal Bank Of Canada cut their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Robert W. Baird reduced their price objective on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus target price of $467.08.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 20.50% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $527.07 on Monday. The company’s fifty day moving average is $451.19 and its two-hundred day moving average is $496.65. Medpace Holdings, Inc. has a 12-month low of $306.70 and a 12-month high of $628.92. The company has a market cap of $15.05 billion, a P/E ratio of 33.13, a price-to-earnings-growth ratio of 2.67 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter last year, the firm posted $3.67 earnings per share. Medpace’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.